Education
About Us
Working with TipRanks
Follow Us
Allakos (ALLK)
:ALLK
ALLK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.23 - $1.56
Previous CloseN/A
Volume85.32K
Average Volume (3M)3.96M
Market Cap
$22.34M
Enterprise Value$4.44M
Total Cash (Recent Filing)$66.44M
Total Debt (Recent Filing)$41.47M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
May 07, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.03
Shares Outstanding89,343,636
10 Day Avg. Volume694,819
30 Day Avg. Volume3,959,550
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.72
Enterprise Value/Ebitda-0.03
Forecast
1Y Price Target
$0.33Price Target Upside32.00% Upside
Rating ConsensusHold
Number of Analyst Covering6
---
Allakos News
PremiumCompany Announcements
Allakos Restructures Amid AK006 Program Discontinuation---
Bulls Say, Bears Say
Bulls Say
Mechanism Of ActionThe unique mechanism of AK006 targeting Siglec-6 is anticipated to provide a differentiated safety profile, which is important for otherwise healthy CSU patients.
Safety ProfileAllakos is expected to report data from approximately 20 patients on AK006, highlighting a benign safety profile as a key differentiator.
Bears Say
Clinical Trial FailureAK006 Phase 1 trial fails to show efficacy in CSU.
Workforce ReductionThe Allakos workforce is being reduced by approximately 75%.
---
Ownership Overview
9.23% Insiders
10.67% Mutual Funds
56.16% Other Institutional Investors
19.33% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALLK FAQ
What was Allakos’s price range in the past 12 months?
Allakos lowest stock price was $0.23 and its highest was $1.55 in the past 12 months.
What is Allakos’s market cap?
Allakos’s market cap is $22.34M.
When is Allakos’s upcoming earnings report date?
Allakos’s upcoming earnings report date is May 07, 2025 which is in 57 days.
How were Allakos’s earnings last quarter?
Currently, no data Available
Is Allakos overvalued?
According to Wall Street analysts Allakos’s price is currently Undervalued.
Does Allakos pay dividends?
Allakos does not currently pay dividends.
What is Allakos’s EPS estimate?
Allakos’s EPS estimate is -0.17.
How many shares outstanding does Allakos have?
Allakos has 89,343,636 shares outstanding.
What happened to Allakos’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Allakos?
Currently, no hedge funds are holding shares in ALLK
---
Allakos Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$0.33 (32.00% Upside)
$0.33 (32.00% Upside)
Blogger Sentiment
Bearish
ALLK Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 885.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.5%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.51%
12-Months-Change
Fundamentals
Return on Equity
-121.68%
Trailing 12-Months
Asset Growth
-56.11%
Trailing 12-Months
Company Description
Allakos
Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood, CA.
---
ALLK Stock 12 Month Forecast
Average Price Target
$0.33
▲(32.00% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Crispr Therapeutics AG
―
AnaptysBio
―
Kiniksa Pharmaceuticals
―
Best Analysts Covering ALLK
1 Year
1 Year Success Rate
4/10 ratings generated profit
1 Year Average Return
-15.60%
assigned a buy rating 4 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -15.60% per trade.
---